In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 15_Supplement ( 2015-08-01), p. 1987-1987
Abstract:
Breast cancer is one of the most common malignancies with increasing incidence every year and a leading cause of death among women. Although early stage breast cancer can be effectively treated, there are limited numbers of treatment options available for patients with advanced and metastatic disease. The breast cancer associated antigen NY-BR-1 was identified by a serological screening strategy (SEREX). NY-BR-1 is expressed in the majority ( & gt;70%) of breast tumors as well as metastases, in normal breast tissue, in testis, and occasionally in prostate tissue. NY-BR-1 was confirmed as an immunogenic antigen as we could detect NY-BR-1 specific spontaneous humoral and cellular immune responses in several breast cancer patients. However, biological function, regulatory mechanisms, and interaction partners of NY-BR-1 are still unknown. Therefore, we combined integrative functional analysis (genomics, transcriptomics and epigenetics) and experiments to unravel the transcriptional regulation of NY-BR-1 and to detect its function within the mammary gland. As numerous binding sites for nuclear hormone receptors (e.g. Estrogen Receptor alpha, Progesterone receptor and Glucocorticoid receptor) and CpG islands were predicted within the promoter sequence of NY-BR-1, primary-tissues from breast reductions or tumor cells obtained from pleural effusions were treated with different hormones (Estradiol, Dexamethasone, Progesterone, Retinoic acid, Vitamin D) or with the HDAC inhibitors Valproic acid, Trichostatin A and the demethylating agent 5´Aza-Deoxycytidine in order to analyze the transcriptional regulation of NY-BR-1. Additionally, we analyzed the methylation status at various sites within the promoter region of NY-BR-1 using EpiTyper MassARRAY technology and publicly available resources such as the TCGA database. Here, we present preliminary results of our analysis and evaluate their implication for further investigation of NY-BR-1. Citation Format: Julia Bitzer, Zeynep Kosaloglu, Niels Halama, Claudia Ziegelmeier, Tina Lerchl, Anna Spille, Maria Pudenz, Eva Koellensperger, Stefan Eichmueller, Wolfram Osen, Andreas Schneeweiss, Frederik Marmé, Inka Zoernig, Dirk Jaeger. Molecular characterization of the breast cancer-associated antigen NY-BR-1. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1987. doi:10.1158/1538-7445.AM2015-1987
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2015-1987
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2015
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Bookmarklink